Sinovac Biotech Ltd. (SVA)
-NasdaqGS | Prev Close: | 3.40 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | 3.77 x 1000 |
|---|
| 1y Target Est: | 3.70 |
|---|
| Beta: | 0.67 |
|---|
| Next Earnings Date: | 28-May-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 1.72 - 5.09 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 497,466 |
|---|
| Market Cap: | 187.31M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.27 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial ResultsPR Newswire(Fri, May 17)
- Sinovac Biotech appoints Ernst & Young Hua Ming China as external auditortheflyonthewall.com(Wed, May 15)
- Sinovac Appoints Ernst & Young Hua Ming Llp China as External AuditorPR Newswire(Wed, May 15)
- Sinovac Presents at the UBS Global Healthcare Conference in May 2013PR Newswire(Tue, May 14)
- SINOVAC BIOTECH LTD FinancialsEDGAR Online Financials(Fri, May 3)
- Scientists Infect Chicks in Race to Halt Bird Flu Spreadat Bloomberg(Wed, May 1)
- Sinovac Files Annual Report on Form 20-FPR Newswire(Tue, Apr 30)
- Sinovac posts 4Q loss as expenses riseAP(Thu, Apr 18)
- Why Sinovac Is Poised to Keep Pulling Backat Motley Fool(Thu, Apr 18)
- Sinovac Biotech's CEO Discusses F4Q2012 Results - Earnings Call Transcriptat Seeking Alpha(Thu, Apr 18)
- Sinovac Reports Unaudited Fourth Quarter and Full Year 2012 Financial ResultsPR Newswire(Thu, Apr 18)
- Sinovac EV71 Vaccine Phase III Top-Line Results Presented at 13th Annual World Vaccine Congress & ExpoPR Newswire(Thu, Apr 18)
- Q4 2012 SINOVAC BIOTECH LTD Earnings Release - Before Market OpenCCBN(Thu, Apr 18)
- Sinovac Receives Commercial Approval in Mexico for Seasonal Flu VaccinePR Newswire(Thu, Apr 18)
- Bird Flu Fears Mount in China as Herbal Remedies Run Outat Bloomberg(Wed, Apr 17)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 3.81 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.21 |
|---|
| Quarterly EPS Est
(Mar-13)
: | -0.10 |
|---|
| Mean Recommendation*: | 3.0 |
|---|
| PEG Ratio (5 yr expected): | -1.30 |
|---|
Business Summary
Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines for hepatitis A, hepatitis B, and influenza viruses in the People's Republic of China.
View More